BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soresi M, Giannitrapani L, D’Antona F, Florena AM, Spada EL, Terranova A, Cervello M, D’Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006; 12(16): 2563-2568 [PMID: 16688802 DOI: 10.3748/wjg.v12.i16.2563] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 91] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Kern L, Mittenbühler MJ, Vesting AJ, Ostermann AL, Wunderlich CM, Wunderlich FT. Obesity-Induced TNFα and IL-6 Signaling: The Missing Link between Obesity and Inflammation-Driven Liver and Colorectal Cancers. Cancers (Basel) 2018;11:E24. [PMID: 30591653 DOI: 10.3390/cancers11010024] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
2 Kanterman J, Sade-Feldman M, Baniyash M. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol. 2012;22:307-318. [PMID: 22387003 DOI: 10.1016/j.semcancer.2012.02.008] [Cited by in Crossref: 125] [Cited by in F6Publishing: 116] [Article Influence: 13.9] [Reference Citation Analysis]
3 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
4 Narazaki M, Kishimoto T. The Two-Faced Cytokine IL-6 in Host Defense and Diseases. Int J Mol Sci 2018;19:E3528. [PMID: 30423923 DOI: 10.3390/ijms19113528] [Cited by in F6Publishing: 59] [Reference Citation Analysis]
5 Nasr MY, Ali Deeb AS, Badra G, El Sayed IH. Lack of Any Relationship Between Circulating Autoantibodies and Interleukin–6 Levels in Egyptian Patients Infected with the Hepatitis C Virus. Asian Pac J Cancer Prev 2016;17:4977-9. [PMID: 28032726 DOI: 10.22034/APJCP.2016.17.11.4977] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Zhang M, Chua MS, Hu J, Li H, Zhang S, Wu L, Han B. High Inflammatory Factor Grading Predicts Poor Disease-Free Survival in AJCC Stage I-II Hepatocellular Carcinoma Patients After R0 Resection. Cancer Manag Res 2019;11:10623-32. [PMID: 31908534 DOI: 10.2147/CMAR.S230386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Bergmann J, Müller M, Baumann N, Reichert M, Heneweer C, Bolik J, Lücke K, Gruber S, Carambia A, Boretius S, Leuschner I, Becker T, Rabe B, Herkel J, Wunderlich FT, Mittrücker HW, Rose-John S, Schmidt-Arras D. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. Hepatology 2017;65:89-103. [PMID: 27770462 DOI: 10.1002/hep.28874] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 14.2] [Reference Citation Analysis]
8 Metwaly HA, Al-Gayyar MM, Eletreby S, Ebrahim MA, El-Shishtawy MM. Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma. Sci Pharm. 2012;80:179-188. [PMID: 22396913 DOI: 10.3797/scipharm.1110-07] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
9 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
10 Théret N, Bouezzedine F, Azar F, Diab-Assaf M, Legagneux V. ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma Microenvironment. Cancers (Basel) 2021;13:1563. [PMID: 33805340 DOI: 10.3390/cancers13071563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
12 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
13 Ng SSW, Zhang H, Wang L, Citrin D, Dawson LA. Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity. NPJ Precis Oncol 2020;4:17. [PMID: 32695883 DOI: 10.1038/s41698-020-0124-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
14 Gong J, Zhang JP, Li B, Zeng C, You K, Chen MX, Yuan Y, Zhuang SM. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene. 2013;32:3071-3079. [PMID: 22824797 DOI: 10.1038/onc.2012.318] [Cited by in Crossref: 135] [Cited by in F6Publishing: 139] [Article Influence: 15.0] [Reference Citation Analysis]
15 Kammoun HL, Allen TL, Henstridge DC, Kraakman MJ, Peijs L, Rose-John S, Febbraio MA. Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice. PLoS One 2017;12:e0179099. [PMID: 28632778 DOI: 10.1371/journal.pone.0179099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Lepiller Q, Tripathy MK, Di Martino V, Kantelip B, Herbein G. Increased HCMV seroprevalence in patients with hepatocellular carcinoma. Virol J. 2011;8:485. [PMID: 22032643 DOI: 10.1186/1743-422x-8-485] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
17 Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T, Hayakawa Y, Kinoshita H, Yamakado M, Kato N. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer. 2009;125:2264-2269. [PMID: 19585572 DOI: 10.1002/ijc.24720] [Cited by in Crossref: 114] [Cited by in F6Publishing: 112] [Article Influence: 9.5] [Reference Citation Analysis]
18 Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121-124. [PMID: 17615358 DOI: 10.1126/science.1140485] [Cited by in Crossref: 1224] [Cited by in F6Publishing: 1166] [Article Influence: 87.4] [Reference Citation Analysis]
19 Giannitrapani L, Soresi M, Balasus D, Licata A, Montalto G. Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol 2013; 19(16): 2449-2455 [PMID: 23674845 DOI: 10.3748/wjg.v19.i16.2449] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
20 Schumacher N, Rose-John S, Schmidt-Arras D. ADAM-Mediated Signalling Pathways in Gastrointestinal Cancer Formation. Int J Mol Sci 2020;21:E5133. [PMID: 32698506 DOI: 10.3390/ijms21145133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
22 Koo BW, Lim DJ, Oh AY, Na HS. Retrospective Comparison between the Effects of Propofol and Inhalation Anesthetics on Postoperative Recurrence of Early- and Intermediate-Stage Hepatocellular Carcinoma. Med Princ Pract 2020;29:422-8. [PMID: 32074612 DOI: 10.1159/000506637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, Shalapour S, Seki E, Yost SE, Jepsen K, Frazer KA, Harismendy O, Hatziapostolou M, Iliopoulos D, Suetsugu A, Hoffman RM, Tateishi R, Koike K, Karin M. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013;155:384-396. [PMID: 24120137 DOI: 10.1016/j.cell.2013.09.031] [Cited by in Crossref: 289] [Cited by in F6Publishing: 275] [Article Influence: 36.1] [Reference Citation Analysis]
24 Kur P, Kolasa-Wołosiuk A, Misiakiewicz-Has K, Wiszniewska B. Sex Hormone-Dependent Physiology and Diseases of Liver. Int J Environ Res Public Health 2020;17:E2620. [PMID: 32290381 DOI: 10.3390/ijerph17082620] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
25 Maegdefrau U, Arndt S, Kivorski G, Hellerbrand C, Bosserhoff AK. Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma. Lab Invest 2011;91:1615-23. [PMID: 21863061 DOI: 10.1038/labinvest.2011.123] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
26 Mikuła T, Sapuła M, Jabłońska J, Kozłowska J, Stańczak W, Krankowska D, Wiercińska-Drapało A. Significance of Heparin-Binding Protein and D-dimers in the Early Diagnosis of Spontaneous Bacterial Peritonitis. Mediators Inflamm 2018;2018:1969108. [PMID: 30363905 DOI: 10.1155/2018/1969108] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
27 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
28 Servais FA, Kirchmeyer M, Hamdorf M, Minoungou NWE, Rose-John S, Kreis S, Haan C, Behrmann I. Modulation of the IL-6-Signaling Pathway in Liver Cells by miRNAs Targeting gp130, JAK1, and/or STAT3. Mol Ther Nucleic Acids 2019;16:419-33. [PMID: 31026677 DOI: 10.1016/j.omtn.2019.03.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
29 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
30 Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14:109-119. [PMID: 18261959 DOI: 10.1016/j.molmed.2007.12.007] [Cited by in Crossref: 462] [Cited by in F6Publishing: 472] [Article Influence: 35.5] [Reference Citation Analysis]
31 Hammad LN, Abdelraouf SM, Hassanein FS, Mohamed WA, Schaalan MF. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis? J Immunotoxicol. 2013;10:380-386. [PMID: 23350952 DOI: 10.3109/1547691x.2012.758198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
32 Qiu B, Wang J, Yu Y, Zhen C, Gu J, Liu W, Wen Y, Chen L, Gao Y, Xia Q, Kong X. DJ-1 promotes development of DEN-induced hepatocellular carcinoma and proliferation of liver cancer cells. Oncotarget 2017;8:8499-511. [PMID: 28036277 DOI: 10.18632/oncotarget.14293] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
33 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
34 Zhang J, Cheng J, Zeng Z, Wang Y, Li X, Xie Q, Jia J, Yan Y, Guo Z, Gao J, Yao M, Chen X, Lu F. Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma. Oncotarget 2015;6:42040-52. [PMID: 26547929 DOI: 10.18632/oncotarget.5969] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
35 Liu F, Zhang W, Yang F, Feng T, Zhou M, Yu Y, Yu X, Zhao W, Yi F, Tang W. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Sci Rep. 2016;6:21260. [PMID: 26879559 DOI: 10.1038/srep21260] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
36 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
37 Sánchez A, Fabregat I. Genetically modified animal models recapitulating molecular events altered in human hepatocarcinogenesis. Clin Transl Oncol 2009;11:208-14. [DOI: 10.1007/s12094-009-0342-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
38 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
39 Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol 2010;6:1771-9. [PMID: 21142662 DOI: 10.2217/fon.10.127] [Cited by in Crossref: 205] [Cited by in F6Publishing: 192] [Article Influence: 20.5] [Reference Citation Analysis]
40 Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 2015;43:400-410. [PMID: 25519488 DOI: 10.1124/dmd.114.061093] [Cited by in Crossref: 104] [Cited by in F6Publishing: 102] [Article Influence: 14.9] [Reference Citation Analysis]
41 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
42 Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T. The role of microRNAs in human liver cancers. Semin Oncol. 2011;38:752-763. [PMID: 22082761 DOI: 10.1053/j.seminoncol.2011.08.001] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 7.9] [Reference Citation Analysis]
43 Guerra AD, Yeung OWH, Qi X, Kao WJ, Man K. The Anti-Tumor Effects of M1 Macrophage-Loaded Poly (ethylene glycol) and Gelatin-Based Hydrogels on Hepatocellular Carcinoma. Theranostics 2017;7:3732-44. [PMID: 29109772 DOI: 10.7150/thno.20251] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
44 Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in Liver Cirrhosis. Int J Mol Sci 2017;18:E1392. [PMID: 28661458 DOI: 10.3390/ijms18071392] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
45 Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012;3:236-60. [PMID: 22470194 DOI: 10.18632/oncotarget.466] [Cited by in Crossref: 123] [Cited by in F6Publishing: 122] [Article Influence: 13.7] [Reference Citation Analysis]
46 Zhang M, Zhang S, Yang Z, Hu J, Hu W, Sun P, Wu L, Han B. Association between the expression levels of IL-6 and IL-6R in the hepatocellular carcinoma microenvironment and postoperative recurrence. Oncol Lett 2018;16:7158-65. [PMID: 30546452 DOI: 10.3892/ol.2018.9557] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
47 Giannitrapani L, Soresi M, Giacalone A, Campagna ME, Marasà M, Cervello M, Marasà S, Montalto G. IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS. 2011;15:183-186. [PMID: 21329460 DOI: 10.1089/omi.2010.0093] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
48 Othman MS, Aref AM, Mohamed AA, Ibrahim WA. Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients. ISRN Hepatol 2013;2013:412317. [PMID: 27335826 DOI: 10.1155/2013/412317] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
49 Jang JW, Oh BS, Kwon JH, You CR, Chung KW, Kay CS, Jung HS. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012;60:686-693. [PMID: 22906998 DOI: 10.1016/j.cyto.2012.07.017] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 7.2] [Reference Citation Analysis]
50 Lee JK, Bettencourt R, Brenner D, Le TA, Barrett-Connor E, Loomba R. Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study. PLoS One 2012;7:e34218. [PMID: 22514624 DOI: 10.1371/journal.pone.0034218] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
51 Firtina Karagonlar Z, Koç D, Şahin E, Avci ST, Yilmaz M, Atabey N, Erdal E. Effect of adipocyte-secreted factors on EpCAM+/CD133+ hepatic stem cell population. Biochem Biophys Res Commun 2016;474:482-90. [PMID: 27131739 DOI: 10.1016/j.bbrc.2016.04.137] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
52 Meirow Y, Kanterman J, Baniyash M. Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate. Front Immunol 2015;6:523. [PMID: 26528286 DOI: 10.3389/fimmu.2015.00523] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
53 Shakiba E, Ramezani M, Sadeghi M. Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis. Clin Exp Hepatol 2018;4:182-90. [PMID: 30324143 DOI: 10.5114/ceh.2018.78122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
54 Yamada K, Mito F, Matsuoka Y, Ide S, Shikimachi K, Fujiki A, Kusakabe D, Ishida Y, Enoki M, Tada A, Ariyoshi M, Yamasaki T, Yamato M. Fluorescence probes to detect lipid-derived radicals. Nat Chem Biol 2016;12:608-13. [DOI: 10.1038/nchembio.2105] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
55 Yuan K, Lei Y, Chen HN, Chen Y, Zhang T, Li K, Xie N, Wang K, Feng X, Pu Q, Yang W, Wu M, Xiang R, Nice EC, Wei Y, Huang C. HBV-induced ROS accumulation promotes hepatocarcinogenesis through Snail-mediated epigenetic silencing of SOCS3. Cell Death Differ 2016;23:616-27. [PMID: 26794444 DOI: 10.1038/cdd.2015.129] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
56 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
57 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
58 Yang L, Wei C, Li Y, He X, He M. miR-224 is an early-stage biomarker of hepatocellular carcinoma with miR-224 and miR-125b as prognostic biomarkers. Biomark Med 2020;14:1485-500. [PMID: 33155836 DOI: 10.2217/bmm-2020-0099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Miyakoshi M, Yamamoto M, Tanaka H, Ogawa K. Serine 727 phosphorylation of STAT3: an early change in mouse hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine. Mol Carcinog 2014;53:67-76. [PMID: 22911886 DOI: 10.1002/mc.21949] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
60 Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK, Sung JJ, Chan HL. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124:2766-2770. [PMID: 19267406 DOI: 10.1002/ijc.24281] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 11.3] [Reference Citation Analysis]
61 Wang YC, Xu GL, Jia WD, Han SJ, Ren WH, Wang W, Liu WB, Zhang CH, Chen H. Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression. Inflammation. 2012;35:143-149. [PMID: 21302136 DOI: 10.1007/s10753-011-9299-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
62 Zekri AR, Bahnassy AA, Abdel-Wahab SA, Khafagy MM, Loutfy SA, Radwan H, Shaarawy SM. Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV-genotype-4. J Gastroenterol Hepatol. 2009;24:416-428. [PMID: 19054267 DOI: 10.1111/j.1440-1746.2008.05699.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
63 Messex JK, Byrd CJ, Liou GY. Signaling of Macrophages that Contours the Tumor Microenvironment for Promoting Cancer Development. Cells 2020;9:E919. [PMID: 32283687 DOI: 10.3390/cells9040919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
64 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
65 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
66 Deng Y, Li M, Wang J, Xie L, Li T, He Y, Lu Q, Li R, Tan A, Qin X. Susceptibility to hepatocellular carcinoma in the Chinese population--associations with interleukin-6 receptor polymorphism. Tumour Biol. 2014;35:6383-6388. [PMID: 24668548 DOI: 10.1007/s13277-014-1863-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
67 Dibra D, Mishra L, Li S. Molecular mechanisms of oncogene-induced inflammation and inflammation-sustained oncogene activation in gastrointestinal tumors: an under-appreciated symbiotic relationship. Biochim Biophys Acta 2014;1846:152-60. [PMID: 24821201 DOI: 10.1016/j.bbcan.2014.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
68 Balaha M, Kandeel S, Barakat W. Carvedilol suppresses circulating and hepatic IL-6 responsible for hepatocarcinogenesis of chronically damaged liver in rats. Toxicology and Applied Pharmacology 2016;311:1-11. [DOI: 10.1016/j.taap.2016.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
69 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
70 Naseem S, Hussain T, Manzoor S. Interleukin-6: A promising cytokine to support liver regeneration and adaptive immunity in liver pathologies. Cytokine Growth Factor Rev 2018;39:36-45. [PMID: 29361380 DOI: 10.1016/j.cytogfr.2018.01.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
71 Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, Lan PC, Yang MH, Chang TS, Huang YH. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res 2019;38:474. [PMID: 31771617 DOI: 10.1186/s13046-019-1442-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
72 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
73 Yu S, Sun L, Wang H, Jiang J, Zhou Q. Autonomic regulation of imbalance-induced myocardial fibrosis and its mechanism in rats with cirrhosis. Exp Ther Med 2021;22:1040. [PMID: 34373726 DOI: 10.3892/etm.2021.10472] [Reference Citation Analysis]
74 Tang S, Liu Z, Zhang Y, He Y, Pan D, Liu Y, Liu Q, Zhang Z, Yuan Y. Rather than Rs1800796 polymorphism, expression of interleukin-6 is associated with disease progression of chronic HBV infection in a Chinese Han population. Dis Markers 2013;35:799-805. [PMID: 24371367 DOI: 10.1155/2013/508023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
75 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
76 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
77 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
78 Knüpfer H, Preiss R. Lack of Knowledge: Breast Cancer and the Soluble Interleukin-6 Receptor. Breast Care (Basel). 2010;5:177-180. [PMID: 21049067 DOI: 10.1159/000314248] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
79 Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol. 2016;64:1403-1415. [PMID: 26867490 DOI: 10.1016/j.jhep.2016.02.004] [Cited by in Crossref: 305] [Cited by in F6Publishing: 299] [Article Influence: 61.0] [Reference Citation Analysis]
80 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
81 Nagashima T, Maruyama A, Kamata Y, Minota S. Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection. Rheumatol Int 2012;32:2231-2. [DOI: 10.1007/s00296-011-2060-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
82 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
83 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [PMID: 25632846 DOI: 10.1007/s00204-015-1461-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
84 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [DOI: 10.1007/s00204-015-1461-5] [Reference Citation Analysis]
85 Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology. 2014;26:54-74. [PMID: 24552665 DOI: 10.1016/j.smim.2014.01.001] [Cited by in Crossref: 319] [Cited by in F6Publishing: 317] [Article Influence: 45.6] [Reference Citation Analysis]
86 Fiorucci M, Boulant S, Fournillier A, Abraham JD, Lavergne JP, Paranhos-Baccala G, Inchauspé G, Bain C. Expression of the alternative reading frame protein of Hepatitis C virus induces cytokines involved in hepatic injuries. J Gen Virol. 2007;88:1149-1162. [PMID: 17374758 DOI: 10.1099/vir.0.82575-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
87 Ribera J, Rodríguez-Vita J, Cordoba B, Portolés I, Casals G, Casals E, Jiménez W, Puntes V, Morales-Ruiz M. Functionalized cerium oxide nanoparticles mitigate the oxidative stress and pro-inflammatory activity associated to the portal vein endothelium of cirrhotic rats. PLoS One 2019;14:e0218716. [PMID: 31233564 DOI: 10.1371/journal.pone.0218716] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
88 Liu Y, Liu A, Xu Z, Yu W, Wang H, Li C, Lin J. XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells. Apoptosis 2011;16:502-10. [PMID: 21311975 DOI: 10.1007/s10495-011-0578-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
89 Malvoisin E, Livrozet JM, Makloufi D, Vincent N. Soluble chemokine receptor CXCR4 is present in human sera. Anal Biochem 2011;414:202-7. [PMID: 21440527 DOI: 10.1016/j.ab.2011.03.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
90 Mourtzikou A, Alepaki M, Stamouli M, Pouliakis A, Skliris A, Karakitsos P. Evaluation of serum levels of IL-6, TNF-α, IL-10, IL-2 and IL-4 in patients with chronic hepatitis. Inmunología 2014;33:41-50. [DOI: 10.1016/j.inmuno.2014.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Liu Y, Gao S, Du B, Wang J. Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis. Tumor Biol 2014;35:3551-61. [DOI: 10.1007/s13277-013-1469-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]